LGND vs. EXAS, HALO, MDGL, ALKS, IONS, FOLD, DVAX, BCRX, MNKD, and CLDX
Should you be buying Ligand Pharmaceuticals stock or one of its competitors? The main competitors of Ligand Pharmaceuticals include Exact Sciences (EXAS), Halozyme Therapeutics (HALO), Madrigal Pharmaceuticals (MDGL), Alkermes (ALKS), Ionis Pharmaceuticals (IONS), Amicus Therapeutics (FOLD), Dynavax Technologies (DVAX), BioCryst Pharmaceuticals (BCRX), MannKind (MNKD), and Celldex Therapeutics (CLDX). These companies are all part of the "biotechnology" industry.
Ligand Pharmaceuticals vs.
Exact Sciences (NASDAQ:EXAS) and Ligand Pharmaceuticals (NASDAQ:LGND) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends, analyst recommendations and community ranking.
In the previous week, Exact Sciences had 4 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 10 mentions for Exact Sciences and 6 mentions for Ligand Pharmaceuticals. Exact Sciences' average media sentiment score of 1.37 beat Ligand Pharmaceuticals' score of 1.23 indicating that Exact Sciences is being referred to more favorably in the media.
88.8% of Exact Sciences shares are owned by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 1.4% of Exact Sciences shares are owned by insiders. Comparatively, 5.9% of Ligand Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Ligand Pharmaceuticals has a net margin of 29.68% compared to Exact Sciences' net margin of -37.29%. Ligand Pharmaceuticals' return on equity of 4.95% beat Exact Sciences' return on equity.
Exact Sciences has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500. Comparatively, Ligand Pharmaceuticals has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500.
Exact Sciences currently has a consensus price target of $70.83, suggesting a potential upside of 50.42%. Ligand Pharmaceuticals has a consensus price target of $147.00, suggesting a potential upside of 31.64%. Given Exact Sciences' higher probable upside, research analysts clearly believe Exact Sciences is more favorable than Ligand Pharmaceuticals.
Ligand Pharmaceuticals has lower revenue, but higher earnings than Exact Sciences. Ligand Pharmaceuticals is trading at a lower price-to-earnings ratio than Exact Sciences, indicating that it is currently the more affordable of the two stocks.
Exact Sciences received 435 more outperform votes than Ligand Pharmaceuticals when rated by MarketBeat users. Likewise, 73.11% of users gave Exact Sciences an outperform vote while only 70.59% of users gave Ligand Pharmaceuticals an outperform vote.
Summary
Ligand Pharmaceuticals beats Exact Sciences on 10 of the 18 factors compared between the two stocks.
Get Ligand Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ligand Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:LGND) was last updated on 3/24/2025 by MarketBeat.com Staff
